Used by physicians to support over 2.5 million health plan members in the US and Puerto Rico, the Oncology Analytics e-Prior Authorization platform is updated daily to accurately reflect more than 6,000 oncology treatment protocols for anti-cancer treatment across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy and supportive care.
Our board-certified oncologists, radiation oncologists, hematologists, and pharmacists have operationalized protocols that cover all cancer diagnoses, and provide insights and analytics that health plans and providers can leverage to further innovation and improvement in cancer care.
Utilization Management, Purpose Built for Oncology
Oncology Analytics e-Prior Authorization platform, is purpose built for oncology to efficiently evaluate and approve high-quality and high-value treatments for cancer care.
Provides consultation from board-certified hematologists/oncologistsread more
Company achieves 100% score on policies, procedures, and file reviewread more
Former Optum executive joins oncology benefits management and analytics company to accelerate growthread more
Oncology Analytics received a request for Rituxan for the treatment of lymphoma in a 62-year-old patient who presented with weakness and fatigue. After reviewing the medical records, it appeared that the available information did not clearly support the requested treatment. An Oncology Analytics medical director consulted with Dr. John Lister, a Pathologist at Johns Hopkins Hospital and a member of Oncology Analytics Distinguished Academic Advisory Board. Dr. Lister, who specializes in hematologic malignancies, concurred that a diagnosis of lymphoma was not established and that treatment was not indicated. Dr. Lister called the treating physician and after a thorough review of the case, it was agreed that treatment was not needed.
Outcome: Rituxan is used to treat a variety of lymphomas. However, this patient did not have evidence of lymphoma. Rituxan has been associated with fatal infusion reactions, kidney failure, bowel obstruction, infections, and other severe side effects. Administering Rituxan would have subjected the patient to the risk of complications without any associated benefit.
Savings: Approximately $6,200 per treatment or approximately $74,000 over 2 years.